Drug Database
TC

Tc-99m depreotide (Techtide P829 / NeoSpect / NeoTect)

✓ Approved

GE Healthcare · Small Molecule · Small Molecule

What is Tc-99m depreotide?

Tc-99m depreotide is a small molecule developed by GE Healthcare. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesTechtide P829, NeoSpect, NeoTect
CompanyGE Healthcare
Drug ClassSmall Molecule, Polypeptide, Imaging Agents, Radiopharmaceutical
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, GE Healthcare

Therapeutic Indications

Tc-99m depreotide is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Uterine cancer✓ Approved

Related Research Articles

PubMedJournal of pain research2026-11-11

An Exploratory Three-Arm Randomized Controlled Trial: The Clinical Effects of Tai Chi, Baduanjin, and Health Education in the Management of Knee Osteoarthritis.

Zeng Tao T, Chen Zi-Liang ZL, Zhou Yao-Hui YH, Liu Wei-Qi WQ

This three-arm randomized controlled trial aimed to investigate the comparative clinical effects of Tai Chi (TC), Baduanjin(BDJ), and Health Education(HE) for controlling symptoms and restoring physical function in individuals diagnosed with knee osteoarthritis(KOA). This randomized controlled trial was conducted on patients with KOA, who were randomly allocated 1:1:1 to three groups (40 participants per group, total randomized n=120): TC, BDJ, or HE. The study lasted 48 weeks, comprising a 12-week intervention phase and a 36-week follow-up. The primary outcomes were the pain, stiffness, and physical function subscales of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Secondary outcomes included the Berg Balance Scale, 6-minute walk test, and the SF-36 quality-of-life assessment. All measures were evaluated at weeks 12, 24, and 48. The primary analysis utilized a linear mixed model based on the modified intention-to-treat (mITT) population (n=116; TC n=38, BDJ n=39, HE n=39), including six participants with partial post-baseline follow-up data. The per-protocol population (n=110) was used for sensitivity analysis. No statistically significant between-group differences in primary outcomes-WOMAC pain, stiffness, and physical function-were detected between the TC and BDJ groups across 12, 24 and 48week assessments (P> 0.05). Compared with HE, TC yielded a mean reduction in WOMAC pain of -3.22 points (95% CI -3.96 to -2.48; P < 0.001), and BDJ yielded a mean reduction of -3.04 points (95% CI -3.78 to -2.30; P < 0.001), indicating superior pain relief for both exercise interventions. Both TC and BDJ groups demonstrated significantly greater improvements compared to the HE group across all time points (P < 0.05). A similar trend was evident in the secondary outcomes. Regular TC and BDJ practice effectively improved the pain, stiffness, and physical function of older adults with KOA, enhanced their balance and walking endurance, and elevated their quality of life. Although no statistically significant difference was detected between TC and BDJ, both exercises showed greater clinical improvements relative to the HE control. These findings support the integration of TC and BDJ as effective, potentially low-cost, non-pharmacological therapies into clinical practice for the long-term management of KOA.The trial was registered in International Traditional Medicine Clinical Trial Registry (ITMCTR), http://itmctr.ccebtcm.org.cn/, identifier ITMCTR2025000409.

PMID 43011836
Read full article →
PubMedFrontiers in endocrinology2026-11-11

Case Report: A longitudinal single-patient observation of metabolic changes during thyrotoxicosis due to toxic multinodular goiter in type 2 diabetes.

Rajab Hussein A HA

Thyrotoxicosis can worsen glucose regulation and is also associated with lower circulating total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C), a metabolic pattern that may be less readily recognized in routine diabetes care. We report a woman aged 51 years at first presentation, with approximately 20 years of type 2 diabetes mellitus and previously diagnosed thyrotoxicosis due to toxic multinodular goiter, who self-referred to our endocrine clinic on September 10, 2024 seeking help with poor glycemic control before planned thyroid surgery. A recent glycated hemoglobin (HbA1c) was 11.8% (105 mmol/mol), she had lost approximately 17 kg, and she reported marked hunger, frequent snacking, heat intolerance, sweating, tremor, insomnia, irritability, palpitations, polyuria, and polydipsia. Dietary contributors were addressed, glimepiride was replaced with pioglitazone, and metformin was increased. Before basal insulin was introduced, fasting plasma glucose (FPG) and HbA1c improved to 183.4 mg/dL (10.2 mmol/L) and 8.9% (74 mmol/mol) on May 6, 2025 while thyroid hormone concentrations also improved. When thyrotoxicosis subsequently worsened on September 15, 2025, free triiodothyronine (FT3) was 15.5 pmol/L and free thyroxine (FT4) was 3.8 ng/dL (48.9 pmol/L), FPG rose to 293.7 mg/dL (16.3 mmol/L) and HbA1c to 12.1% (109 mmol/mol), and TC and directly measured LDL-C were 121.9 mg/dL (3.2 mmol/L) and 45 mg/dL (1.2 mmol/L), respectively. With continued antithyroid treatment and later intensification of diabetes therapy, thyroid biochemistry and glycemia improved; by August 24, 2026, FT3 was 6.1 pmol/L, FT4 1.5 ng/dL (19.3 pmol/L), FPG 117.8 mg/dL (6.5 mmol/L), HbA1c 9.4% (79 mmol/mol), TC 151.4 mg/dL (3.9 mmol/L), and LDL-C 66 mg/dL (1.7 mmol/L). The patient preferred thyroidectomy and developed compressive symptoms, but surgery remained delayed because of glycemic concerns and long surgical appointment intervals. This longitudinal pattern suggests that thyrotoxicosis may have contributed to glycemic instability and the low LDL-C and TC pattern. Concurrent diabetes-treatment changes prevent attribution to thyroid status alone, but the case highlights that behavioral contributors and physiological drivers can coexist and that thyrotoxicosis should be considered when metabolic deterioration appears disproportionate to behavioral factors.

PMID 43011010
Read full article →
PubMedNano letters2026-11-11

Record-Breaking Elemental Superconductivity in Tetralayer Kagome Borophene.

Liu Yingnan Y, Liu Yan Y, Duan Renyu R, Wang Menghui M et al.

Superconductivity above the liquid-nitrogen temperature remains rare in two-dimensional elemental crystals, where strong covalent bonding often yields high phonon frequencies but insufficient electron-phonon coupling. Here, using first-principles calculations and fully anisotropic Migdal-Eliashberg theory, we predict tetralayer kagome borophene (TKB) stabilized by ABAB covalent stacking, as a liquid-nitrogen-temperature elemental superconductor. With a predicted critical temperature of ∼100-113 K, TKB sets a record-high value among previously reported elemental superconductors. Unlike known high-Tc boron-based superconductors dominated by in-plane σ-bonding states and high-frequency in-plane B-B stretching modes, TKB realizes an out-of-plane s-pz-bonding-mediated pairing mechanism, in which interlayer s-pz bonding states at the Fermi level are strongly coupled to low-frequency out-of-plane vibrations of boron atoms. These results reveal a distinct out-of-plane pairing channel in multilayer borophene and establish covalent stacking engineering as a potential route for high-Tc superconductivity in two-dimensional materials.

PMID 43012608
Read full article →
PubMedEJNMMI physics2026-11-11

Patient-specific modeling enables specific activity optimization to maximize tumor absorbed dose in transarterial radioembolization.

Huesa-Berral Carlos C, Dawson Robert J RJ, Sabet Hamid H, Rodríguez-Fraile Macarena M et al.

Transarterial radioembolization (TARE) is evolving from palliative to curative in the management of hepatocellular carcinoma (HCC). Alongside, there is a growing need to develop personalized and predictive dosimetry strategies to maximize the therapeutic effect. The objective of this study was to evaluate the feasibility of a novel framework, MIDOS, to design patient-specific optimal TARE plans. A retrospective cohort of fourteen TARE patients with solitary HCC who had [99mTc]Tc-MAA SPECT-CT was analyzed, including segmental and lobar administrations. For each patient, tumor and perfused area segmentations were included in a liver vasculature model. In our simulations, microspheres were stochastically assigned in cluster patterns to tumor or normal liver tissue, with probabilities proportional to flow and modulated by tumor and normal liver uptake models. Simulation results were employed to generate synthetic [99mTc]Tc-MAA SPECT images that were compared with patient images using the relative activity errors in tumor and normal tissue, tumor-to-normal ratio (TNR), and gamma analysis (10%/10 mm) of normal tissue distribution. Virtual 90Y treatment plans were generated using the prescribed activity across a range of specific activities (40-4000 Bq/bead), from which personalized treatment planning curves for TNR and tumor and normal liver mean absorbed dose were derived. Synthetic [99mTc]Tc-MAA SPECT images presented relative errors below 2% for overall tumor activity, normal liver activity, and TNR. Pass rates of 10%/10 mm for normal tissue distribution were above 90% in all patients. Treatment planning curves revealed patient- and scenario-specific optima in TNR, corresponding to maximal tumor mean dose and minimal normal liver mean dose, with substantial inter-patient variability in dose sensitivity to specific activity. This study shows the feasibility of MIDOS as a framework for quantitative treatment optimization in TARE under different clinical scenarios. This allows systematic optimization of treatment planning curves that maximize TNR and tumor mean dose as a function of the 90Y specific activity.

PMID 43009669
Read full article →
PubMedAngewandte Chemie (International ed. in English)2026-11-11

Quantitative Pertechnetate Capture by a Bambusuril-based Material: From Seawater Decontamination to Radiopharmaceutical Solutions.

Šusterová Michaela M, Claude Guilhem G, Rupf Susanne M SM, Kataev Evgeny A EA et al.

Pertechnetate is central to nuclear waste management (99 TcO 4 -) and nuclear medicine (99m TcO 4 -), yet its selective capture from saline media at ultratrace concentrations remains an unsolved challenge. Here we show that bambusuril macrocycles binds 99 TcO 4 - in water with micromolar affinity, forming well-defined host-guest complexes. Immobilization of bambusuril on silica translates this molecular recognition into efficient solid-phase extraction, enhancing binding under highly competitive conditions of seawater and medicinal generator eluents. The resulting material quantitatively captures 99 TcO 4 - from saline solutions at femtomolar concentrations and enables direct elution of preconcentrated 99 TcO 4 - using commercial nuclear medicine kit formulations. These findings establish bambusuril-based materials as the first supramolecular platform for ultratrace pertechnetate capture from highly competitive saline media, bridging molecular recognition with applications in nuclear medicine and environmental remediation.

PMID 43012525
Read full article →
PubMedBreast cancer research : BCR2026-11-11

CD39-associated myeloid-T-cell coordination within an immunoregulatory neighborhood linked to treatment resistance in triple-negative breast cancer.

Hu Zihan Z, Zheng Haoyu H, Jin Cheng C, Shang Guoguo G et al.

Immunotherapy efficacy in triple-negative breast cancer (TNBC) remains limited, partly due to mechanisms of immune suppression within the tumor microenvironment (TME). Ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1, encoding cluster of differentiation 39, CD39) is a key immunoregulatory ectonucleotidase, but its treatment-associated distribution and coordination across myeloid and T-cell states in TNBC remain incompletely characterized. We re-analyzed a single-cell RNA sequencing (scRNA-seq) dataset comprising 156120 immune cells from 27 tumor and metastatic samples across 14 patients with TNBC. Trajectory and cell-cell communication analyses were complemented by NicheNet, independent single-cell and bulk transcriptomic validation, CosMx spatial transcriptomics, and multiplex immunofluorescence. CD39 protein expression and its association with survival were evaluated in an independent cohort of 112 patients with TNBC using immunohistochemistry (IHC), Kaplan-Meier analysis, and multivariable Cox proportional hazards regression. Three signed-R2-based summary indices-treatment contribution (TC), ENTPD1 dynamic index (EDI), and tumor response index (TRI)-were applied to summarize treatment-associated immune dynamics. ENTPD1 expression was observed across macrophage and regulatory T-cell states, including CD4+CD39+ Tregs. Higher macrophage ENTPD1 expression was associated with M2-related programs, attenuated stimulator of interferon genes (STING)-type I interferon signaling, and reduced antigen-presentation programs. Cell-cell communication analysis revealed preferential interactions between myeloid cells and CD4+CD39+ T cells. Inferred lymphotoxin (LT) signaling involving CD4+CD39+ T cells and myeloid populations was higher in non-responders. Cross-cohort and patient-level analyses supported coordinated CD39-associated immune programs, while spatial transcriptomics and representative multiplex immunofluorescence imaging visualized the implicated populations within shared tumor regions. In the independent IHC cohort, high tissue-level CD39 expression remained independently associated with shorter overall survival (OS) after adjustment for age group and American Joint Committee on Cancer (AJCC) stage. ENTPD1/CD39 was associated with coordinated myeloid and T-cell states, an adenosine-related immunoregulatory context, and reduced response to anti-programmed death-ligand 1 (PD-L1) therapy plus chemotherapy in TNBC. These findings support further evaluation of ENTPD1/CD39-associated immune states in the context of immune checkpoint blockade (ICB). High tissue-level CD39 expression was independently associated with shorter OS in an independent clinical cohort.

PMID 43010016
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about Tc-99m depreotide